Skip to main content

Eli Lilly — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

158
Companies
$6.3B
Total invested
$57.7M
Avg. check
16
Industries
Biotechnology 23Health Care 14Therapeutics 12Medical 9Life Science 6Pharmaceutical 3+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 158
Circle Pharma
September 2024

Circle Pharma is a biotechnology company creating bioavailable macrocyclic peptide therapeutics that target protein-protein interactions.

Biotechnology · San Francisco$90.0M Series D
Aktis Oncology
September 2024

Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.

Biotechnology · Boston$175.0M Series B
Sitryx Therapeutics
September 2023

Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.

Biotechnology · Oxford$39.0M Series A
Volastra Therapeutics
September 2025

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

Biotechnology · New York$30.1M Series A
HAYA Therapeutics
September 2025

HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.

Biotechnology · LausanneGrant
Avidity Biosciences
September 2025

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

Biotechnology · San Diego$690.0M Post-IPO Equity
Artax Biopharma
August 2024

Artax Biopharma is a biopharmaceutical company that develops new therapies for autoimmune and inflammatory diseases.

Biopharma · Cambridge$8.0M Convertible Note
Amber Bio
August 2023

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits.

Biotechnology · San Francisco$26.0M Seed
DELFI Diagnostics
July 2022

DELFI's AI platform uses whole-genome sequencing to detect cancer-associated cfDNA fragmentation patterns in the blood.

Artificial Intelligence (AI) · Palo Alto$225.0M Series B
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonVenture - Series Unknown
Mozart Therapeutics
June 2023

Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.

Biotechnology · Seattle$25.0M Series A
Signify Bio
June 2025

Signify Bio is a biotechnology company harnessing the human body for the production of in situ protein therapeutics.

Hospital · Dallas$15.0M Venture - Series Unknown
Lycia Therapeutics
June 2026

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Biotechnology · South San Francisco$75.0M Series D
ProQR Therapeutics
June 2026

ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.

Biotechnology · Leiden$59.2M Post-IPO Equity
Absci
June 2026

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Artificial Intelligence (AI) · Vancouver$100.0M Post-IPO Equity
TRIMTECH Therapeutics
June 2026

TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.

Biotechnology · Cambridge$14.0M Seed
AltPep
June 2023

AltPep provides a novel approach for tackling amyloid diseases, with diagnostic, therapeutic and anti-biofilm applications.

Biotechnology · Seattle$52.9M Series B
Laverock Therapeutics
June 2026

Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies.

Biotechnology · Stevenage$3.0M Grant
LTZ Therapeutics
May 2026

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

Biotechnology · San Francisco$38.0M Venture - Series Unknown
Cabaletta Bio
May 2026

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

Biotechnology · Philadelphia$150.0M Post-IPO Equity
AbCellera
May 2023

AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.

Biotechnology · Vancouver$515.8M Grant
Remedium Bio
May 2026

Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.

Biotechnology · Needham$1.5M Venture - Series Unknown
Seraxis
May 2025

Seraxis is a privately owned biotechnology company.

Biotechnology · GermantownGrant
Stylus Medicine
May 2025

Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.

Biotechnology · Cambridge$85.0M Series A

Where Eli Lilly invests

Biotechnology23
Health Care14
Therapeutics12
Medical9
Life Science6
Pharmaceutical3

About Eli Lilly's portfolio

How many companies has Eli Lilly invested in?

Eli Lilly has invested in 158 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Eli Lilly invest in?

Eli Lilly's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 16 different industry categories.

What is Eli Lilly's largest investment?

Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post-IPO Equity round. Eli Lilly's total known invested capital is $6.3B.

What is the average investment size for Eli Lilly?

Eli Lilly's average investment size is $57.7M across its portfolio of 158 companies.

What are Eli Lilly's most recent investments?

Recent Eli Lilly portfolio additions include Circle Pharma, Aktis Oncology, Sitryx Therapeutics, Volastra Therapeutics, HAYA Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 158 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →